Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JWCAR104
- Development stage
- Unknown
- Lead developer
- Juventas Cell Therapy
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
JWCAR104 is an autologous, dual-target chimeric antigen receptor (CAR) T-cell therapy developed by Juventas Cell Therapy. It is engineered to simultaneously target two distinct B-cell antigens, CD19 and CD22. This dual-targeting strategy is intended to enhance therapeutic efficacy and prevent disease relapse caused by antigen escape, a phenomenon where cancer cells lose expression of a single target antigen to evade the immune system. By binding to both CD19 and CD22 on the surface of malignant B-cells, JWCAR104 triggers T-cell activation and targeted cytotoxicity. It is currently being investigated in Phase 1 clinical trials for patients with B-cell Non-Hodgkin Lymphoma (B-NHL).
- Other names
- CD19/CD22 dual-target CAR-T cell therapyJuventas CD19/CD22 CAR-T
02
Targets
CD22 (Cluster of Differentiation 22)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on JWCAR104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JWCAR104.